health π¬ New RNA approach tackles CF mutations
Researchers developed chemically engineered suppressor tRNAs packaged in lung-targeted lipid nanoparticles to treat nonsense mutation cystic fibrosis. This work was conducted by Jingan Chen and colleagues in preclinical models, including mouse models and patient-derived organoids. The study demonstrated that the treatment successfully restored functional CFTR protein production in these various cellular systems. This method aims to correct protein production at the mutation site instead of editing the underlying DNA. However, further research is needed regarding the safety of repeated doses due to observed inflammation.